



The over expression of thioredoxin during malignancies

Shahaboddin Shabani (MD)^{1*}, Navid Nourizadeh (MD)², Mohammadsaleh Soltankhah (MD)¹

¹*Sinus and Surgical Endoscopic Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran*

²*Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran*

ARTICLE INFO

ABSTRACT

Article type

Review article

Article history

Received: 13 Mar 2014

Revised: 12 Apr 2014

Accepted: 22 Apr 2014

Keywords

Malignancy

Thioredoxin reductase

Thioredoxin system

Thioredoxin system comprised of thiorexin and NADPH dependent thiorexin reductase, is responsible for redox regulation of cells by controlling the apoptosis, proliferation and other vital processes of cells. The efficacy of thioredoxin system has been represented in a wide range of physiological and biological reactions in bacteria, yeast, plants, mammals and etc. including DNA synthesis, regulation of transcription factors, protein repairing, regulating the photosynthesis and controlling the apoptosis and preventing oxidative stresses, filamentous phage assembly, immune-modulating, neuronal survival, pregnancy and birth and many other physiological and biological functions. The up-regulation of thioredoxin has been observed in various malignancies, which was associated with tumor angiogenesis and development. In this regard, the thioredoxin system has become a putative target in new chemotherapeutic methods. In this study, we mentioned various features of thioredoxin system in malignant cells and reviewed the articles which have evaluated the expression rate of thioredoxin system in malignancies.

Please cite this paper as:

Shabani S, Nourizadeh N, Soltankhah M. The over expression of thioredoxin during malignancies. *Rev Clin Med.* 2014;1(4):218-224.

Introduction

Thioredoxin system

Thioredoxins (Trx) are among redox proteins, which are firstly isolated from *Escherichia coli* in 1964. These proteins are widely distributed in nature from prokaryotes to

eukaryotes. The thioredoxin system comprised of thioredoxin (Trx), flavoprotein thioredoxin reductase (TrxR) and NADPH, keeps the thioredoxin in its reduced state

***Corresponding author:** Shahaboddin Shabani.
Department of otorhinolaryngology - head and neck surgery, Mashhad University of Medical Sciences, Mashhad, Iran
E-mail: ShabaniSh891@mums.ac.ir
Tel: 09155008806

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

and acts as a high capacity hydrogen transport system. This system contributes in cellular functions and regulatory mechanisms through stabilizing disulfide bonds and facilitating the thiol/disulfide exchange reactions as antioxidants. The function of thioredoxin system is crucial in regulating the redox hemostasis, which results in the maintenance of the cellular viability and function. The expression of Trx has been detected during the fetal development that is the indication of its role in fetal cellular function (1). Trx is a multifunctional redox regulator with intracellular and extracellular functions. It would be secreted due to various stimuli (X-ray radiation, ultraviolet (UV) light, tumor necrosis factor α and etc.) to protect and regulate the cellular responses (2). The secretion of Trx have been identified in different mammalian cells such as placental, liver, secretory, leucocytes and keratinocytes of the skin due to various stimuli (3). TrxR is a selenoprotein, which is a flavoenzyme that reduces the Trx dependence on NADPH.

The efficacy of Trx system has been presented in a wide range of physiological and biological reactions in bacteria, yeast, plants, mammals and etc. including DNA synthesis, regulation of transcription factors, protein repairing, regulating the photosynthesis and controlling the apoptosis and preventing oxidative stresses, filamentous phage assembly, immune-modulating, neuronal survival, pregnancy and birth and many other functions. Peroxiredoxins and methionine sulfoxide reductases are known as two direct targets for the disulfide bond reduction of Trx isophorms (4).

Selenium (Se), which is a biologically important factor, is crucial for maintaining the optimum cellular function and could be found in proteins as selenocysteine. Although Se has shown some preventive effect on tumor development and invasion, its

high concentrations might have cytotoxic effects. In the study of Erkhembayar et al. selenium-dependent increase of TrxR activity was observed in rat by administrating Se supplementation. In this study, it was supposed that TrxR might act as a carrier, which supported the supplementary Selenite to exert its effect.

Cytosolic isophorms (Trx1 and TrxR1), mitochondrial isophorms (Trx2 and TrxR2) and another third isophorm (TGR), all have been expressed in mammals with cells specific expression patterns (5,6). There are two kind of cytosolic Trx (Trx1 and Trx80), which have differentiated due to their immune-modulator functions regarding co-cytokines or chemokines. All the Trx proteins contain two catalytic cystine residues in their conserved active site with the (-Cys-Gly-Pro-Cys-) amino acid sequence (7).

Human thioredoxin-1 (Trx-1) is a protein with 104 amino acids and 12 k-Da molecular weight, which have been cloned from various mammalian species. In human, the Trx gene localization has been mapped to chromosome 9 at band 9q32 (8). Thioredoxin-2 (Trx-2) contains 166 amino acids with the 18 k-Da molecular weight, which have been cloned previously (9). In normal cells, the preventive effects of TrxR on the occurrence of malignancies have been shown in different ways that lead to the maintenance of DNA structure form mutations and oxidative damages and regulating the redox homeostasis. TrxR has shown supporting effect on the function of p53 (a well-known tumor suppressor) and the selenocysteine residue of the TrxR has also shown cancer inhibitory effects. These are among various pathways that TrxR involves in maintaining the redox status of the cells.

Trx contributions in malignancies

According to literature, Trx is neither indicated as a direct oncogen nor contains

any mutagenic properties due to its expression in many normal cells and tissues. It has stimulative and inhibitory effects on growth and apoptosis of normal cell, respectively and it would lead to development of the malignancy in cancerous cells.

Adult T-cell leukemia-derived factor (an interleukin-2 receptor inducer) is known as human thioredoxin homologue and can increase the proliferation of the malignant cells (10).

In various unusual situations such as cardiopulmonary bypass operations (11), rheumatoid arthritis, HIV and etc. the increased levels of plasma Trx system has been observed which make it as a putative target in tumor therapy (12,13).

It is proved that the presence of Trx is essential in tumorigenesis but the level of Trx involvement is different based on the type of the cancer. Based on different studies and using several techniques, mostly immunohistochemistry, the Trx expression has been evaluated in various types of human cancer cells such as lung, colorectal, cervix, gastric, hepatocellular and well-differentiated squamous cell carcinomas of skin in comparison with their related normal tissues. This has resulted in several fold increase of the Trx concentration in plasma and serum of cancer cells (14-18).

Based on these studies, it has been speculated that the Trx overexpression might be induced by the increased oxidative stress and hypoxic conditions resulted from the carcinoma cells. It is also concluded that tumor cell with overexpression of Trx showed higher proliferation and higher durability than tumor cells with no expression of Trx.

Miyazaki et al. revealed that 40 Cytokines such as interleukin-6 (IL-6) and interferon have revealed inducible role in increasing the Trx expression in condition such as HIV. During in-vivo situations, the lysis of red blood cells is considered an important source of elevating the Trx despite it is not known as the

major cause of the increased level of plasma Trx. This is due to the high content of Trx in erythrocytes (21). Monocytes/macrophages and endothelial cells are the other sources of plasma Trx (22). Platelet dysfunction in Hermansky-Pudlak syndrome has resulted in elevated Trx concentrations (23).

Increasing the growth, angiogenesis and anti-apoptotic activities in tumor cells

In cancer cells, the overexpression of Trx might result in more aggressive phenotypes by accelerating the cell proliferation and decreasing the apoptosis or even modulating the cell genetic arrangements.

The Trx system might pose its growth promoting effects by altering the transcription factor expression and the consequent protein kinases activity cascades, modulating the integrin and adhesion molecules activity or even through the direct influence on the DNA synthesis (19). Based on immunohistochemistry studies, Trx would act as an autocrine growth promoting adult T-cell Leukemia-derived factor (ADF) in extracellular environment, or a stimulant which induces the growth of B cells which was indicated in hepatocellular carcinoma (10). In one study considering the Trx effects on breast cancer cells proliferation, it was suggested that Trx acted as a growth factor on cancerous cells and stimulated cells to produce their own growth factors (self-stimulating growth factor production) for more cell proliferation and tumor development (24). TrxR plays a major role in counteracting the processes of apoptosis in cancer cells including modulating through inhibition of the Ask-1 signaling cascade or supporting the antioxidant pathways such as peroxiredoxin activity (25).

TrxR links to the process of angiogenesis which is a vital phenomenon for successful tumor development. Based on the studies, this association might be through the increasing of hypoxia-inducible factor-1 (HIF-1) and

VEGF (Vascular endothelial growth factor) following the up-regulation of TrxR (26).

TrxR a putative chemotherapy target

Resistance to chemotherapy is another feature of cancer cells with high expression level of TrxR. Due to the prominent role of the TrxR in various levels of cancer development, TrxR has become an attractive target in chemotherapy methods and there were variety of studies, which aimed to discover new medicines for diminishing the up-regulated TrxR in every malignancy.

Methods in malignancy suppressing, which are associated to the TrxR, might affect the selenium part of the enzyme, directly knock down the TrxR or apply the medicines, which inhibit the TrxR activities.

There are various synthetic and natural origin products, which have shown TrxR

inhibitory effects. Some inhibitors used for cancer diminishing through inactivation of TrxR, are listed in Table 1.

The metal containing inhibitors have exerted their effects in a DNA-independent way and through inhibiting the TrxR and inserting cytotoxicity influence against cancer cells, which results in anti-proliferative effects (27).

Red drinking wine (contains contains myricetin and quercetin as flavonoids) is considered to induce the apoptosis due to its high content of antioxidants (28). Theaflavins are the polyphenols in black tea that cause its antioxidant and antitumor effects (29). Anthranoids obtained from plants and bacteria, Curcumin from *Curcuma longa* and Mansonone F obtained from *Ulmus pumila*, have shown anti-tumor properties (30,31).

In the study of Baker et al. administrating PX-12 (1-methylpropyl 2-imidazolyl disul-

Table 1. Different drugs used for suppressing the TrxR activity in cancer cells

Drugs	Evaluated cell line
Metal-containing inhibitors (metallo drugs) Gold-containing inhibitors Aurano-fin gold-phosphine complexes gold-triphenylphosphane complexes gold-triazaphosphaadamantane complexes gold-NHC (N-heterocyclic carbene) complexes gold-thiosemicarbazones complexes Ruthenium-containing inhibitors PMRU20 RUMA NAMIA PMRU27	Applied in human ovarian cancer cells A549, MCF-7, HeLa, HL60 MCF-7, A549, A431 MCF-7, A549, A431 MCF-7, HT-29, HCT-116, HEP-G2 HL-60, MCF-7, HCT-116, Jurkat HT29, MCF-7 and A549
Naturally occurring products Flavonoids and Polyphenols Red drinking wine Tea (black tea) Anthranoids Hypericin (HYP) pseudohypericin (PHYP) Curcumin Mansonone F Cinnamaldehyde acylfulvene	HEK-293, H157, A549, HCT116
Newly emerged inhibitors Indolequinones Porphyrins Statins	ES936 and ES939 Rottlerin Protoporphyrin IX human pancreatic cancer cell lines human liver biopsies

fide) was proposed as a novel method in decreasing the plasma concentration of the TrxR through inhibiting the expression of TrxR and finally the VEGF of the tumor cells. In this study, PX-12 was administrated in patients with different malignancies such as colorectal and pancreatic cancers. The SELDI-TOF (Surface-enhanced laser desorption ionization time-of-flight) mass spectrometry method was applied for evaluating the plasma changes regarding the TrxR concentration. It was concluded that PX-12 reduce the plasma concentration of TrxR and VEGF, specifically in patients who had shown high plasma levels of these two proteins (32). In a randomized trial, PX-12 was administrated in patients with advanced pancreatic cancer, which did not result in noticeable antitumor activity (33).

It has been suggested that the apoptosis would be increased in tumor cells by targeting TrxR due to elevated oxidant susceptibility. It was also recommended that signaling pathways of ASK-1 and NF- α B would lose their regulation by diminishing the TrxR and finally it resulted in increased apoptosis due to the activation of JNK and p38 signaling cascades (34).

Manipulating through molecular approaches is another way to reduce the upregulation of TrxR and reverse the tumorigenic phenotype of the cancer cells to the normal cells.

In the study of Yoo et al. preventing the malignancy development was achieved by direct action on TrxR. In this study, a reduction in the TrxR level was observed as a result of knocked-down TrxR in lung cancerous cells via siRNA, which were based on the PhosphorImager method outcomes, by using ⁷⁵Se for the labeling of the LLC1 (Lewis Lung Carcinoma) cell line of the mouse lung carcinoma. Further analysis in this study showed various phenotypical changes of cancer cells similar to the normal cells including a considerable reduced rate of cell proliferation and the monolayer growing

of cells, which were tightly attached to the culture dish (35).

Conclusion

Although there are various studies regarding the effects of thioredoxin system in the process of cancer development, further investigations could increase our knowledge about the association between thioredoxin system upregulation and the cancerous cell functions. More comprehensive information improves the therapeutic techniques in cancer prevention.

Acknowledgement

We would like to thank Clinical Research Development Center of Ghaem Hospital for their assistant in this manuscript. This study was supported by a grant from the Vice Chancellor for Research of the Mashhad University of Medical Sciences for the research project as a medical student thesis with approval number of 910047.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Fujii S, Nanbu Y, Konishi I, et al. Immunohistochemical localization of adult T-cell leukaemia-derived factor, a human thioredoxin homologue, in human fetal tissues. *Virchows Arch A Pathol Anat Histopathol.* 1991;419:317-326.
2. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. *Annu Rev Immunol.* 1997;15:351-369.
3. Soderberg A, Sahaf B, Rosen A. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. *Cancer Res.* 2000;60:2281-2289.
4. Arner ES, Holmgren A. The thioredoxin system in cancer. *Semin Cancer Biol.* 2006;16:420-426.
5. Damdimopoulos AE, Miranda-Vizuete A, Treuter E, et al. An alternative splicing variant of the selenoprotein thioredoxin reductase is a modulator of estrogen signaling. *J Biol Chem.* 2004;279:38721-38729.
6. Rundlof AK, Janard M, Miranda-Vizuete A, et al. Evidence for intriguingly complex

- transcription of human thioredoxin reductase 1. *Free Radic Biol Med*. 2004;36:641-456.
7. Luthman M, Holmgren A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. *Biochemistry*. 1982;21:6628-6633.
 8. Heppell-Parton A, Cahn A, Bench A, et al. Thioredoxin, a mediator of growth inhibition, maps to 9q31. *Genomics*. 1995;26:379-381.
 9. Miranda-Vizueté A, Damdimopoulos AE, Pedrajas JR, et al. Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization. *Eur J Biochem*. 1999;261:405-412.
 10. Nakamura H, Masutani H, Tagaya Y, et al. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. *Cancer*. 1992;69:2091-2097.
 11. Nakamura H, Vaage J, Valen G, et al. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. *Free Radic Biol Med*. 1998;24:1176-1186.
 12. Yoshida S, Katoh T, Tetsuka T, et al. Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF- α -induced production of IL-6 and IL-8 from cultured synovial fibroblasts. *J Immunol*. 1999;163:351-358.
 13. Nakamura H, De Rosa S, Roederer M, et al. Elevation of plasma thioredoxin levels in HIV-infected individuals. *Int Immunol*. 1996;8:603-611.
 14. Berggren M, Gallegos A, Gasdaska JR, et al. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. *Anticancer Res*. 1996;16:3459-3466.
 15. Gasdaska PY, Oblong JE, Cotgreave IA, et al. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. *Biochim Biophys Acta*. 1994;1218:292-296.
 16. Kawahara N, Tanaka T, Yokomizo A, et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. *Cancer Res*. 1996;56:5330-5333.
 17. Grogan TM, Fenoglio-Prieser C, Zeheb R, et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. *Hum Pathol*. 2000;31:475-481.
 18. Wakita H, Yodoi J, Masutani H, et al. Immunohistochemical distribution of adult T-cell leukemia-derived factor/thioredoxin in epithelial components of normal and pathologic human skin conditions. *J Invest Dermatol*. 1992;99:101-107.
 19. Miyazaki K, Noda N, Okada S, et al. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. *Biotherapy*. 1998;11:277-288.
 20. Park BJ, Cha MK, Kim IH. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses. *BMC Res Notes*. 2014;7:7.
 21. Holmgren A, Luthman M. Tissue distribution and subcellular localization of bovine thioredoxin determined by radioimmunoassay. *Biochemistry*. 1978;17:4071-4077.
 22. Gougeon ML, Montagnier L. Apoptosis in AIDS. *Science*. 1993;260:1269-1270.
 23. Schallreuter KU, Witkop CJ. Thioredoxin reductase activity in Hermansky-Pudlak syndrome: a method for identification of putative heterozygotes. *J Invest Dermatol*. 1988;90:372-377.
 24. Gasdaska JR, Berggren M, Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. *Cell Growth Differ*. 1995;6:1643-1650.
 25. Chen X, Tang W, Liu S, et al. Thioredoxin-1 phosphorylated at T100 is needed for its anti-apoptotic activity in HepG2 cancer cells. *Life Sci*. 2010;87:254-260.
 26. Welsh SJ, Bellamy WT, Briehl MM, et al. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1 α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. *Cancer Res*. 2002;62:5089-5095.
 27. Ronconi L, Marzano C, Zanello P, et al. Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties. *J Med Chem*. 2006;49:1648-1657.
 28. Wallenborg K, Vlachos P, Eriksson S, et al. Red wine triggers cell death and thioredoxin reductase inhibition: effects beyond resveratrol and SIRT1. *Exp Cell Res*. 2009;315:1360-1371.
 29. Du Y, Wu Y, Cao X, et al. Inhibition of mammalian thioredoxin reductase by black tea and its constituents: implications for anticancer actions. *Biochimie*. 2009;91:434-444.
 30. Tulp M, Bohlin L. Rediscovery of known natural compounds: nuisance or goldmine? *Trends Pharmacol Sci*. 2005;26:175-177.
 31. Chew EH, Nagle AA, Zhang Y, et al. Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. *Free Radic Biol Med*. 2010;48:98-111.
 32. Baker AF, Dragovich T, Tate WR, et al. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.

- J Lab Clin Med. 2006;147:83-90.
33. Ramanathan RK, Abbruzzese J, Dragovich T, et al. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. *Cancer Chemother Pharmacol.* 2011;67:503-509.
 34. Myers JM, Myers CR. The effects of hexavalent chromium on thioredoxin reductase and peroxiredoxins in human bronchial epithelial cells. *Free Radic Biol Med.* 2009;47:1477-1485.
 35. Yoo MH, Xu XM, Carlson BA, et al. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. *J Biol Chem.* 2006;281:13005-13008.